Related Experiment Video
Updated: Jan 28, 2026

07:42
A Data-Driven Approach to Quantifying Immune States in Sepsis
Published on: February 7, 2025
496
How we manage haemostasis during sepsis.
Marie Scully1,2, Marcel Levi2,3
1Department of Haematology, University College London Hospital, London, UK.
British Journal of Haematology
|March 5, 2019
Summary
Sepsis can trigger blood clotting issues, potentially leading to disseminated intravascular coagulation (DIC). This condition progresses from blood clots to bleeding due to factor consumption, impacting organ function.
Area of Science:
- Hematology
- Critical Care Medicine
- Pathophysiology
Background:
- Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection.
- Sepsis can activate the coagulation system, potentially leading to disseminated intravascular coagulation (DIC).
Purpose of the Study:
- To explore the relationship between sepsis and coagulation system activation.
- To discuss the progression from thrombotic to bleeding states in sepsis-induced DIC.
- To highlight the role of scoring systems and laboratory parameters in diagnosing DIC.
Main Methods:
- Review of the pathophysiology of sepsis-associated coagulation abnormalities.
- Analysis of clinical features, including thrombocytopenia and hypofibrinogenemia.
- Discussion of diagnostic scoring systems for DIC.
- Consideration of hemostatic support strategies.
Main Results:
- Sepsis initially causes thrombosis in small and medium vessels, leading to organ dysfunction.
- Continued coagulation activation consumes factors, prolonging coagulation parameters and causing thrombocytopenia.
- Severe cases involve hypofibrinogenemia and fibrinolytic overactivation, resulting in a bleeding phenotype.
Conclusions:
- Disseminated intravascular coagulation (DIC) is a severe complication of sepsis, characterized by a shift from thrombosis to bleeding.
- Routine laboratory parameters and scoring systems aid in DIC diagnosis and risk assessment.
- Management involves supporting hemostasis through medical and blood product interventions.
Related Concept Videos
Impression Management Techniques I: Managing Appearances
214
Appearance is a multidimensional aspect of self-presentation that encompasses observable attributes such as clothing, grooming, speech, and nonverbal behavior. These elements are often strategically managed to align with socially constructed expectations in different settings. For instance, individuals tailor their appearance during job interviews, social gatherings, or athletic events to meet the perceived norms of those environments.Contextual Adaptation and Social SignalsThe research...
214
Tonsillitis II: Management
425
This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
425
Management of Insomnia
612
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
612
Managing Impressions
169
Impression management encompasses individuals' deliberate efforts to shape how others perceive them during social interactions. This behavior is often employed to conform to social norms, secure approval, or pursue specific goals. While it involves selective self-presentation, it is not necessarily deceptive; individuals frequently present authentic aspects of themselves that align with situational demands.Common strategies include:Ingratiation: where individuals use flattery or agreeableness...
169
Cystic Fibrosis: Management
520
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
520
Angina IV: Management
277
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
277

